Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Shunjiang Yu, CMO
CONTACT
Yuankai Shi, M.D
CONTACT
Lead
Qilu Pharmaceutical Co., Ltd.
The clinical study is a single-arm, phase II, open label, multicenter design in patients with crizotinib-resistant ALK -positive, or crizotinib-resistant/crizotinib-naive ROS1-positive NSCLC.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
